Oral dosing formulations of dideoxy purine nucleosides

Details Oral dosing formulations of dideoxy purine nucleosides Oral dosing formulations of dideoxy purine nucleosides

1997-10-02

1999-03-09

Knode, Marian C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 46, 536 2714, A61K 3170

Patent

active

058801065

ABSTRACT:
Improved oral dosage formulations for acid-labile dideoxy purine nucleoside derivatives such as ddA, ddI, and ddG, have been developed by incorporating selected water-insoluble buffering systems in the formulation. These novel formulations provide reduced mass dosage units in the form of convenient, palatable chewable/dispersible tablets or a dry powder sachet. The reduced mass requirement, necessary to allow tablets of reasonable size, was achieved in part by an unexpected 20 to 25% increase in drug bioavailability resulting from use of the selected buffering systems comprised of an insoluble magnesium antacid agent and either dihydroxyaluminum sodium carbonate or calcium carbonate.

REFERENCES:
patent: 4260596 (1981-04-01), Mackles
patent: 4786505 (1988-11-01), Lovgren et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4935243 (1990-06-01), Borkan et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5087447 (1992-02-01), Racz et al.
Anderson, et al., International J. of Pharmaceutics, 1988, 45: 27-37.
Hoofnagle, et al., NTIS Publication PB89-186217, Method of Treatment of Hepatitis May 1989.
McGowan, et al., Reviews of Infect. Diseases, 1990, Overview of the Preclinical Devel. of an Antiretroviral Drug, 2',3' -Dideoxyinosine. 12 (Supplement 5) : S 513-S 521. (Jul.).
Dolin, et al., Reviews of Infect. Diseases, (1990) 12 Supp 5:S540-S549, 2',3'-Dideoxyinosine in Patients with AIDS or AIDS-Related Complex. (Jul.).
Hartman, et al., Clin. Pharmacol. Ther. (1991) 50: 278-285, II. The Effects of Different Oral Formulations and the Presence of Other Medications.
Anderson et al., "Preformulation Solubility and Kinetic Studies of 2',3'-Dideoxypurine Nucleosides: Potential Anti-AIDS Agents," International Journal of Pharmaceutics, 45, 27-37 (1988).
Hoofnagle et al., "Method of Treatment of Hepatitis," NTIS Publication PB89-186217, Specification of US Patent Application 07/351,502; Patent Application Filing Date--May 15, 1989.
McGowan et al., "Overview of the Preclinical Development of an Antiretroviral Drug, 2', 3'-Dideoxyinosine," Reviews of Infectious Diseases, 12(Suppl. 5), S513-S521 (Jul.-Aug. 1990).
Dolin et al., "2', 3'-Dideoxyinosine in Patients with AIDS or AIDS-Related Complex," Reviews of Infectious Diseases, 12(Suppl. 5), S540-S549 (Jul.-Aug. 1990).
Hartmann et al., "Pharmacokinetics of 2', 3'-Dideoxyinosine in Patients with Severe Human Immunodeficiency Infection. II. The Effects of Different Oral, Formulations and the Presence of Other Medications," Clin. Pharmacol. Ther., 50(3), 278-285 (Sep. 1991).
Yarchoan et al.(II), "In Vivo Activity Against HIV and Favorable Toxicity Profile of 2', 3'-Dideoxyinosine," Science, 245, 412-415 (Jul. 28, 1989).
Rudnic et al., "Oral Dosage Forms," Ch. 89 in Remington's Pharmaceutical Sciences, 18th Edition, Gennaro et al.(eds.), Philadelphia College of Pharamcy and Science, Philadelphia, PA, 1990, only pp. 1633-1638 supplied.

Affiliated with

Also associated with

Rating

Oral dosing formulations of dideoxy purine nucleosides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral dosing formulations of dideoxy purine nucleosides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral dosing formulations of dideoxy purine nucleosides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1321237